Sector News

Novo Nordisk's North American head Jakob Riis to leave

March 3, 2017
Life sciences

Novo Nordisk Jakob Riis FalckNovo Nordisk’s head of North America Operations and president of Novo Nordisk Inc Jakob Riis has resigned.

He will remain with the Danish pharma company for a transitional period, ahead of joining Copenhagen-based health and safety services company Falck as president and CEO on 1 May.
Riis (pictured) joined Novo in 1996 and spent 10 years as the firm’s senior vice president of global marketing, during which he took on additional responsibilities in China and the Pacific region.

However, he only held his US role for seven months, and it will now by filled by Dough Langa, who currently serves as its US senior vice president for market access.

Göran Ando, chairman of Novo’s board of directors, said: “We are of course sad to see Jakob Riis leave. He has done a great job throughout his career in Novo Nordisk, and we wish him all the best.

“We welcome Doug Langa as our new head of North America operations. Doug’s experience in the US pharmaceutical market, his leadership skills and expertise in the area of market access make him the natural successor to Jakob Riis.”

Langa joined Novo in 2011 as senior director, managed markets, from GlaxoSmithKline where he was senior director of payer marketing and prior to that spent the majority of his career at Johnson & Johnson

Source: PMLive

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).